Imidazole propionate is a driver and therapeutic target in atherosclerosis
Overview
Paper Summary
This study found that imidazole propionate (ImP), a metabolite produced by gut microorganisms, is associated with atherosclerosis in mice and humans. While the human data is correlational and derived from cohorts of limited diversity (Spanish and Swedish populations), experiments in mouse models suggest a causal role for ImP in driving atherosclerosis, particularly through activation of the immune response and the mTOR pathway in myeloid cells. Blocking ImP's interaction with the I1R receptor in mice prevented atherosclerosis development.
Explain Like I'm Five
Scientists found that a signal from tiny helpers in our tummies can cause sticky gunk to build up in our blood pipes. They also found a way to stop this gunk from forming in mice!
Possible Conflicts of Interest
Some authors are listed as inventors on a patent application related to antagonists of I1R. FB receives research funding from Biogaia AB and Novo Nordisk A/S, is a co-founder and shareholder of Roxbiosens Inc., and is on the scientific advisory board of Bactolife A/S. FB, KRB, and AC are co-founders and shareholders of Implexion Pharma AB.
Identified Limitations
Rating Explanation
This is a strong study with compelling findings in mouse models and human cohorts, suggesting a potential new target for atherosclerosis therapy. The research employs appropriate methodology and provides valuable insights into the role of gut microbiota in cardiovascular disease. However, limitations related to generalizability and mechanistic understanding in humans prevent a perfect score.
Good to know
This is the Starter analysis. Paperzilla Pro fact-checks every citation, researches author backgrounds and funding sources, and uses advanced AI reasoning for more thorough insights.
Explore Pro →